The FDA told Pharmacyclics Inc. that Xcytrin (motexafin gadolinium) injection in combination with radiation was not approvable to treat patients with non-small-cell lung cancer (NSCLC) whose disease has spread to the brain. (BioWorld Today)

The FDA told Pharmacyclics Inc. that Xcytrin (motexafin gadolinium) injection in combination with radiation was not approvable to treat patients with non-small-cell lung cancer (NSCLC) whose disease has spread to the brain. (BioWorld Today)

Biotechs continued rushing to finalize deals before the year-end, with Human Genome Sciences Inc. and Montreal-based Aegera Therapeutics Inc. teaming up in a $315 million agreement to develop and commercialize cancer cell-killing molecules. (BioWorld Today)

Biotechs continued rushing to finalize deals before the year-end, with Human Genome Sciences Inc. and Montreal-based Aegera Therapeutics Inc. teaming up in a $315 million agreement to develop and commercialize cancer cell-killing molecules. (BioWorld Today)